By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Data detailed on Biotechnology have been presented. According to news reporting originating from Nantong, People's Republic of China, by NewsRx correspondents, research stated, "Simultaneous silencing of multiple up-regulated genes is an attractive and viable strategy to treat many incurable diseases including cancer. Herein we used dual gene targeted siRNA (DGT siRNA) conjugate composed of NET-1 and VEGF siRNA sequences in the same backbone could inhibit growth and angiogenesis HCC."
Our news editors obtained a quote from the research from Nantong University, "DGT siRNA showed a further down regulation on VEGF mRNA and protein levels compared with NET-1 siRNA or VEGF siRNA, but not on NET-1 expression. It also exhibited greater suppression on proliferation and trigger of apoptosis in HepG2 cells than NET-1 siRNA or VEGF siRNA; this could be explained by the significant down regulation of cyclin D1 and Bcl-2. A lower level of ANG2 mRNA and protein was detected in HUVEC cultured with supernatant of HepG2 cells treated with DGT siRNA than that of VEGF siRNA or NET-1 siRNA, resulting in much more inhibited angiogenesis of HUVEC. Tumor growth was inhibited and microvessel density dropped in the xenograft tumor models compared to the untreated controls. NET-1 and VEGF silencing play a key role in inhibiting hepatocellular cell proliferation, promoting apoptosis, and reducing angiogenesis."
According to the news editors, the research concluded: "Simultaneous silencing of NET-1 and VEGF using DGT siRNA construct may provide an advantageous alternative in development of therapeutics for Hepatocellular carcinoma."
For more information on this research see: Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF. Journal of Molecular Histology, 2013;44(4):433-45. Journal of Molecular Histology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Journal of Molecular Histology - www.springerlink.com/content/1567-2379/)
The news editors report that additional information may be obtained by contacting Y.Y. Wu, Dept. of Pathological Anatomy, Nantong University, Nantong, People's Republic of China. Additional authors for this research include L. Chen, G.L. Wang, Y.X. Zhang, J.M. Zhou, S. He, J. Qin and Y.Y Zhu (see also Biotechnology).
Publisher contact information for the Journal of Molecular Histology is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Asia, VEGF, Biotechnology, Nantong, Genetics, Oncology, Angiogenesis, Protein Kinases, Membrane Proteins, Angiogenic Proteins, Cancer Gene Therapy, Phosphotransferases, Growth Factor Receptors, Hepatocellular Carcinoma, People's Republic of China, Receptor Protein Tyrosine Kinases, Vascular Endothelial Growth Factors.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC